Antibody blockade of CLEC12A delays EAE onset and attenuates disease severity by impairing myeloid cell CNS infiltration and restoring positive immunity

Divya Sagar¹, Narendra P. Singh², Rashida Ginwala¹, Xiaofang Huang⁴, Ramila Philip⁴, Mitzi Nagarkatti², Prakash Nagarkatti², Konstantin Neumann⁵, Jürgen Ruland⁵, Allison M. Andrews⁶, Servio H. Ramirez⁶, Zafar K. Khan¹ & Pooja Jain¹

The mechanism of dendritic cells (DCs) recruitment across the blood brain barrier (BBB) during neuroinflammation has been the least explored amongst all leukocytes. For cells of myeloid origin, while integrins function at the level of adhesion, the importance oflectins remains unknown. Here, we identified functions of one C-type lectin receptor, CLEC12A, in facilitating DC binding and transmigration across the BBB in response to CCL2 chemotaxis. To test function of CLEC12A in an animal model of multiple sclerosis (MS), we administered blocking antibody to CLEC12A that significantly ameliorated disease scores in MOG35-55-induced progressive, as well as PLP138-151-induced relapsing-remitting experimental autoimmune encephalomyelitis (EAE) mice. The decline in both progression and relapse of EAE occurred as a result of reduced demyelination and myeloid cell infiltration into the CNS tissue. DC numbers were restored in the spleen of C57BL/6 and peripheral blood of SJL/J mice along with a decreased TH17 phenotype within CD4⁺ T-cells. The effects of CLEC12A blocking were further validated using CLEC12A knockout (KO) animals wherein EAE disease induction was delayed and reduced disease severity was observed. These studies reveal the utility of a DC-specific mechanism in designing new therapeutics for MS.

The central nervous system (CNS) is structured to be an immune-privileged site to remain protected from detrimental insults that can result in immune-mediated inflammation. Focal demyelinated lesions and transected axons in neuroinflammatory disease such as multiple sclerosis (MS) is believed to be mediated by infiltrating inflammatory cells, including CD4⁺ and CD8⁺ T-cells, B cells, and APCs such as dendritic cells (DCs) and macrophages. In a recent study, onset of experimental autoimmune encephalomyelitis (EAE), the mouse model for MS, was shown to coincide with a sudden spike in the number of infiltrating DCs and macrophages in the CNS, the majority of which contained myelin antigen after migration into the CNS.

Amongst the current MS treatments targeting leukocyte infiltration across the blood brain barrier (BBB), natalizumab, a monoclonal antibody against the α-chain of VLA-4, sometimes leads to progressive multifocal leukoencephalopathy arising out of immune suppression and reactivation of the John Cunningham virus within the CNS of certain patients. In the light of these concerns, our approach to find a target to block myeloid cell migration to evade complete immune suppression is novel.
Studies of EAE have long substantiated the pathogenic role of macrophages, but a similar role for DCs has always been postulated. Thus far, there has been no attempt to develop a clinically viable target to impede the migration of DCs and other myeloid cells so as to prevent potential reactivation of encephalitogenic lymphocytes. We established the role of the chemokine CCL2 in the trafficking of DCs across the BBB and showed for the first time the real-time trafficking of DCs in the inflamed spinal cord of animals afflicted with EAE. However, the mechanisms reviewed previously of how circulating DCs access the CNS remain to be investigated. Therefore, we focused our efforts on understanding C-type lectin receptors (CLRs) found on cells of myeloid origin and have dual roles in cell-adhesion and pathogen-recognition, for their potential role influencing cellular trafficking across the BBB.

Our studies revealed CLEC12A, a Src homology region 2 domain-containing phosphatase 1 and 2 (SHP-1 and -2)-associated receptor involved in inhibitory signaling as a key molecule to target on immature DCs trafficking to the CNS prior to becoming activated within the CNS upon encountering myelin antigens. Binding of the CLEC12A receptor to the endothelium was demonstrated to be important for monocyte-derived dendritic cells (MDDCs) that are important in development of inflammatory and autoimmune disease and myeloid DCs (mDCs). In EAE mice, administration of blocking antibody against CLEC12A receptor achieved significant disease attenuation in both progressive and relapsing-remitting EAE models. Reduction in disease severity in antibody-treated mice correlated with reduction in DC accumulation into the CNS tissues, demyelination as well as the TH17 phenotype within CD4+ T-cells. Our results were further validated in the CLEC12A−/− animals wherein mice showed a delayed-onset of disease and significant reduction in disease severity. This study opens up the prospect of selectively regulating DC entry into the CNS using antibody treatment as a new alternative against disease pathogenesis and propagation in multiple sclerosis and other inflammatory/autoimmune diseases.

**Results**

**Differential surface expression of lectins on different DC subsets.** CLR specific antibodies were used to stain and profile DC subsets, MDDCs and mDCs, for expression of CLRs (Fig. 1). Phenotype and activation status of isolated mDCs was confirmed after each isolation (Supplementary Figure 1). Both CD205 (DEC-205) and CD206 (MR), type I CLRs belonging to the mannose receptor (MR) family were expressed on MDDCs and mDCs. CD207 or langerin, type II CLR specific to Langerhans cells and CD303 or BDCA2, a human plasmacytoid DC marker were absent in both subsets. CD209 or DCSIGN (type II), a classic tissue-differentiated DC marker was predictably present on MDDCs but not mDCs (Fig. 1a). DCs also showed expression of ITIM (immunoreceptor tyrosine-based inhibitory motif) associated CLEC4A and CLEC12A receptors and ITAM (immunoreceptor tyrosine-based activation motif) associated CLEC9A receptor. Interestingly, mDCs showed elevated expression of CLEC12A. Low levels of CLEC10A were detected in both MDDCs and mDCs (Fig. 1b).

**C-type lectin receptors are important for binding and transmigration of DCs across brain microvascular endothelium in response to CCL2.** In the multistep paradigm of leukocyte transmigration, while lecits can mediate the tethering and rolling of leukocytes to the vessel wall, presence of a chemottractant ensures the directional pull across the BBB thereby triggering firm attachment of DCs to the endothelial surface. Others and we have previously shown expression of CCR2 on DCs and monocytes allows their migration in response to CCL2, whereas lectins can mediate the tethering and rolling of leukocytes to the vessel wall, presence of a chemotactrant ensures the directional pull across the BBB thereby triggering firm attachment of DCs to the endothelial surface. Others and we have previously shown expression of CCR2 on DCs and monocytes allows their migration in response to CCL2.

Examination of MDDCs, both activated and non-activated, revealed more CCR2 expression in comparison with T cells (Supplementary Figure 2A). We then used TNF-α-activated hCMEC/D3 cells - a brain microvascular endothelial cell line with many close characteristics of the primary cells - and allowed fluorescent dye-labeled DCs to bind to them. hCMEC/D3 cells themselves do not show expression of CLRs of interest (Supplementary Figure 2B). Testing the blocking efficiency of antibodies showed that receptors became unavailable for binding (Supplementary Figure 2C). Blocking CD209 or DCSIGN, CLEC4A, CLEC9A and CLEC12A on DCs, all resulted in reduced fluorescence intensity, indicating decreased binding (Fig. 2a). For BBB set-up, MDDCs were added to CCL2-treated mice correlated with reduction in DC accumulation into the CNS tissues, demyelination as well as the TH17 phenotype within CD4+ T-cells. Our results were further validated in the CLEC12A−/− animals wherein mice showed a delayed-onset of disease and significant reduction in disease severity. This study opens up the prospect of selectively regulating DC entry into the CNS using antibody treatment as a new alternative against disease pathogenesis and propagation in multiple sclerosis and other inflammatory/autoimmune diseases.

**SHP1/2 signaling is important for CCL2-driven migratory phenotype in DCs.** A concerted facilitation of CLR signaling within DCs and CCL2-driven chemoattraction is important for interactions with the BBB in order to enable neuroinvasion. In fact, analysis of the actin cytoskeletal molecular signaling pathway reveals MAPK and F-actin nucleation signaling molecules upon CCL2 treatment as summarized in Table 1 and Fig. 3 (derived from a phosphoproteomic analysis of various biological processes and molecular functions in Supplementary Figure 4A and 4B). CLEC4A and CLEC9A immune cells stained very brightly with phalloidin (a marker for F-actin nucleation), whereas the endothelial cell monolayer stained very diffusely (Fig. 4a) within a transwell system containing CCL2. Further, phalloidin expression on DCs (Fig. 4b) showed increased intensity within 30 m of CCL2 treatment. Besides DCs, only monocytes were (Fig. 4d) (Supplementary Figure 5) found to be responsive to CCL2 treatment.
CLEC12A contains a single ITIM in its cytoplasmic tail that associates with the signaling phosphatases SHP1/2 leading to immune modulation. MDDCs, which showed increased phosphorylation of both SHP-2 and Syk upon exposure to CCL2 (Fig. 4e), were treated with inhibitors to both SHP1/2 and Syk and analyzed for phalloidin expression. Interestingly, inhibition of SHP1/2 reduced CCL2-induced actin polymerization, particularly on DCs expressing Wiskott–Aldrich syndrome protein (WASP) (Fig. 4f), a molecule known to associate with Wiskott–Aldrich syndrome protein (WASP) on DC podosomes⁴. Syk inhibition increased phalloidin expression (Fig. 4d, lower panel). This evidence suggests that ITIM regulated SHP1/2 phosphorylation is important for CCL2 driven migratory response.

Figure 1. Lectin expression profile on human dendritic cell subsets. PBMCs isolated from individual donors were used to obtain MDDCs and mDCs. Representative histograms of (a) lin⁰/HLADR⁺ MDDCs and (b) CD19⁻/CD1c⁺ mDCs showing individual CLR expression profile with expression levels (black) gated on isotype controls (gray). Comparative geometric mean fluorescence intensities (GMFI) are displayed alongside histograms as bar graphs. Each histogram is representative of three individual donors. Bar graphs represent mean levels ±SEM.
Figure 2. Effective CLR blocking impacts binding of DCs to brain endothelium and subsequent transmigration. DCs obtained from PBMCs were pre-treated with monoclonal antibodies fluorescently labeled prior to addition into a 96-well plate containing a confluent monolayer of TNF-α-activated hCMEC/D3 cells for 1 h and washed. Fluorescence was read at the 540 nm wavelength. For transmigration, pre-treated DCs and monocytes were added to the hCMEC/D3 cell monolayer and allowed to transmigrate for 24 h. Reduction in fluorescence intensities upon binding (a) and number of transmigrated cells (b) were observed in MDDCs and mDCs. (c) Bar graph showing number of migrated monocytes. (d) Similarly, migration of mouse splenic DCs across bEnd.3 cells is shown as a bar graph. Significance is represented when *P < 0.05, **P < 0.01 and ***P < 0.001. Bar graphs are representative of two independent experiments run in triplicate. (See also Figures S2 and S3).
Administration of anti-CLEC12A antibody shows significant delay of disease onset, attenuation in clinical symptoms and relapse. Based on evidence from our in vitro studies, we wished to study the effects of blocking the ITIM bearing SHP1/2 associated CLR, CLEC12A, on myeloid immune cells, particularly DCs, on the clinical course of EAE in C57BL/6 mice after immunization with myelin peptides. Notably, EAE mice showed significantly higher levels of CLEC12A expression on myeloid cells within the spleen and cervical lymph nodes (cLNs) compared to control mice (Fig. 5a). Upon MOG 35–55 peptide immunization, C57BL/6 mice showed disease onset on Day 9 that progressively peaked on Days 18–19. To block early invasion of DCs into the CNS, anti-CLEC12A antibody was administered on Day 7 prior to disease onset. First, antibody specificity was tested on ex vivo spleen sections from CLEC12A−/− C57BL/6 mice wherein no staining was observed as opposed to the sections from wild-type mice (Supplementary Figure 6). Alternatively, CLEC4A staining was seen in both the KO and wild-type sections. Anti-CLEC12A antibody treatment not only delayed onset by 2 days, but also significantly attenuated disease severity. Additionally, 50% of body weight was regained after antibody administration (Fig. 5b, right panel).

Since most patients have relapse remitting-MS (RR-MS), we injected anti-CLEC12A antibody after disease onset in a mouse model of RR-EAE (Fig. 5c, left panel). Clinical behavioral scores for mice treated

Table 1. MAPK and F-actin nucleation signaling molecules upon CCL2 treatment.

| Accession ID | Protein name | Peptide in treatment sample | Phosphorylation site | pSR | Xcorr | Pathway |
|--------------|--------------|-----------------------------|----------------------|-----|-------|---------|
| P46734       | Dual specificity mitogen-activated protein kinase 3 | mcDFGISGYLVDvVAK      | M1(Oxidation); C2(Carbamidomethyl); S13(Phospho) | 175 | 5.42  | MAPK    |
| P52564       | Dual specificity mitogen-activated protein kinase 6 | McDFGISGYLVDvVAK      | C2(Carbamidomethyl); S13(Phospho) | 207 | 4.83  | MAPK    |
| O43553       | Receptor-interacting serine/threonine-protein kinase 2 | SPmLNLLQNK             | S3(Phospho)          | 101 | 3.43  | MAPK    |
| Q13177       | Serine/threonine-protein kinase PAK 2 | DGFPSGTPALNAK          | S5(Phospho)          | 96  | 3.56  | MAPK    |
| P47712       | Cytosolic phospholipase A2 | HIVSNDSSD3DDEENHPK     | S10(Phospho)         | 89  | 4.22  | MAPK    |
| Q15418       | Ribosomal protein S6 kinase alpha-1 | KAYSFCGTVEYMAPEVNR     | C6(Carbamidomethyl); T8(Phospho) | 62  | 4.68  | MAPK    |
| P51812       | Ribosomal protein S6 kinase alpha-3 | KAYSFCGTVEYMAPEVNR     | C6(Carbamidomethyl); T8(Phospho) | 62  | 4.68  | MAPK    |
| P51812       | Ribosomal protein S6 kinase alpha-3 | NSIQTDGYEVK           | S2(Phospho)          | 89  | 3.93  | MAPK    |
| Q9UK32       | Ribosomal protein S6 kinase alpha-6 | KAYSFCGTVEYMAPEVNR     | C6(Carbamidomethyl); T8(Phospho) | 62  | 4.68  | MAPK    |
| P46109       | Crk-like protein | DSTCPGDYLYVLSSENSR     | S2(Phospho); C5(Carbamidomethyl) | 110 | 5.4   | MAPK    |
| P46940       | Ras GTPase-activating-like protein IQGAP1 | SKSVKEDSNLTQEK        | S3(Phospho)          | 53  | 4.8   | actin   |
| Q15052       | Rho guanine nucleotide exchange factor 6 | KDSIPQVLLPEEEKLIEETR   | S3(Phospho)          | 100 | 4.03  | actin   |
| Q14155       | Rho guanine nucleotide exchange factor 7 | MSGFIYQGK              | S2(Phospho)          | 102 | 3.25  | actin   |
| P35579       | Myosin-9 | GAGDGSDEEVYDGKADGAEAKPAE | S6(Phospho)          | 60  | 4.25  | actin   |
| Q13177       | Serine/threonine-protein kinase PAK 2 | DGFPSGTPALNAK          | S5(Phospho)          | 96  | 3.56  | actin   |
| P62328       | Thymosin beta-4 | TEQEKNPLPSK           | T3(Phospho)          | 60  | 4.26  | actin   |
| A8MW06       | Thymosin beta-4-like protein 3 | TEQEKNPLPSK           | T3(Phospho)          | 60  | 4.26  | actin   |
| P46109       | Crk-like protein | DSTCPGDYLYVLSSENSR     | S2(Phospho); C5(Carbamidomethyl) | 110 | 5.4   | actin   |
| P35611       | Alpha-adducin | AAVVTLPPPTAPTHK        | S6(Phospho)          | 100 | 3.32  | actin   |
| Q13884       | Beta-1-syntrophin | GSPVSEGWETTPPePR       | S16(Phospho)         | 131 | 5.14  | actin   |
| Q13884       | Beta-1-syntrophin | GSPVSEGWETTPPePR       | S16(Phospho)         | 131 | 5.14  | actin   |
| Q96666       | Neuroblast differentiation-associated protein AHNK | VSMPDVELNLKsPK      | S12(Phospho)         | 90  | 3.94  | actin   |
| P13796       | Plastin-2 | FSvVLGKGGQDLENEGR     | S2(Phospho)          | 127 | 3.93  | actin   |
| Q15149       | Plectin | SsvGssSSYPISPAvSr       | S3(Phospho); S6(Phospho) | 113 | 5.01  | actin   |
| Q15149       | Plectin | SsvGssSSYPISPAvSr       | S2(Phospho); S6(Phospho) | 102 | 5.01  | actin   |
| P11171       | Protein 4.1 | SPRPDAITQGVQAAEGVGLDASAK | T5(Phospho)      | 85  | 5.71  | actin   |
| P11171       | Protein 4.1 | SPRPDAITQGVQAAEGVGLDASAK | T6(Phospho)      | 93  | 5.71  | actin   |
| Q9NYL9       | Tropomodulin-3 | DLDEDEDELANLsETELK   | S12(Phospho)         | 169 | 5.81  | actin   |
| P47736       | Rap1 GTPase-activating protein 1 | AAGISLVPGKsPTR       | S12(Phospho)         | 110 | 4.01  | actin   |
| Q14247       | Sec substrate cortactin | LPSpVYEDAASPK       | S4(Phospho)          | 114 | 3.24  | actin   |
with anti-CLEC12A antibody on Day 14 and Day 21 suggest quite significantly alleviated severity of PLP139–151-mediated disease progression. Remarkably, Day 36 showed significant remission upon treatment compared to untreated mice. Thereafter, a significantly higher relapse score was seen in untreated versus treated mice. Figure 5c (right panel) demonstrates concomitant increase in body weight as treatment alleviates disease symptoms. Importantly, induction of EAE in CLEC12A−/− mice revealed a 7 day delay in disease onset along with reduced disease severity (Fig. 5d).

Anti-CLEC12A antibody treatment reduces DC infiltration within CNS of EAE mice. Histopathology on lumbar spinal cords taken from isotype-treated mice undergoing EAE displayed irregular myelin oligodendrocyte staining indicating severe demyelination as compared to control mice (Fig. 6a). CD11c+ positive DCs in the spinal cord accumulated in much higher numbers in areas with ongoing demyelination as also seen before2. Remarkably, Day 7 anti-CLEC12A antibody treatment shows preservation of myelination and significantly lesser accumulation of DCs. EAE tissues indicated dramatic DC infiltration and direct association with myelin (Fig. 6b), which was much less evident upon anti-CLEC12A antibody treatment. Additionally, infiltration of CD11b+ myeloid cells such as macrophages and CD19+ B cells was also markedly reduced in the Day 7 CLEC12A antibody treated animals (Fig. 6c). Brain tissue of SJL/J mice also revealed increased preservation of myelin and less cellular infiltration upon anti-CLEC12A antibody treatment compared to no treatment (Fig. 6d).

CLEC12A antibody treatment retains and restores DC function in the periphery in EAE mice. Upon quantification of immune cells of C57BL/6 mice, splenocytes revealed higher numbers of CD11c+, CD11c+/CD8α+ and CD11b+ cells within anti-CLEC12A antibody-treated mice compared to isotype-treated EAE mice, suggesting accumulation in the periphery (Fig. 7a). A similar increase in the number of DCs was observed in the cLNs upon antibody treatment (Supplementary Figure 7A). This upregulation was not seen amongst myeloid cells found within splenocytes of SJL/J mice (data not shown). Interestingly, we found a higher percentage of CD11c+ DCs expressing CCR2 in the untreated mice (Supplementary Figure 7B) consistent with a study showing higher chemokinet receptor expression in mDCs of MS patients35. Treatment with anti-CLEC12A antibody was seen to reduce CCR2 expression on these cells (Supplementary Figure 7B). Splenic CD4+ and CD8+ T-cells were not directly affected in numbers upon antibody treatment (Fig. 7a), however, there was a significant decrease in their numbers in the cLNs suggesting reduced T cell trafficking in the brain (Supplementary Figure 7A). Similarly, our analysis of SJL/J mice revealed that the absolute number of CD11c+ DCs increased within peripheral blood along with a reduction in their CCR2 expression levels (Supplementary Figure 7C,D, and E). CD86 and MHCII expression on DCs in blood and periphery of the treated mice did not change indicating that anti-CLEC12A antibody did not have an impact on activation of DCs (Fig. 7b). This was further corroborated with in vitro exposure of CD11c+ cells with anti-CLEC12A antibody (Fig. 7c) where neither CD86 or CD80 levels were affected by treatment.

Next, investigation into effect of the antibody on CD4 and CD8 T cell activation revealed that T cells within the spleen expressed higher CD69, which was reduced by antibody treatment (Fig. 7d). Th1 and T regulatory CD4 T cell phenotypes on splenocytes from anti-CLEC12A antibody-treated EAE mice exhibited reduced IL-17A+ cells compared to untreated EAE mice (Fig. 7e). A closer look at individual responses show that numbers of IL-17A+/CD4+ T-cells and CD25+/FOXP3+ CD4+ T-cells decreased moderately but not significantly between untreated and treated EAE mice upon MOG stimulation. This is perhaps due to the fact that splenocytes were harvested from mice where remission had already set in. SJL/J mice, however, indicated a significant decrease in splenic IL17A+ cells suggesting a dampened TH17 response upon restimulation with PLP139–151 peptide in...
Figure 4. Increased actin polymerization dynamics in DCs upon CCL2 treatment and its decrease upon SHP1/2 inhibition. (a) PBMCs were added to a transwell containing a confluent layer of activated hCMEC/D3 cells in the insert and CCL2 (100 ng/ml) in the lower well. After 2h, transwell was stained for phalloidin-FITC (3 μg) as well as TRITC labeled anti-CLEC4A, -CLEC9A antibodies. Microscopy evidence of intense F-actin expression on cells (co-labeled as yellow) as they appear to be transmigrating between two endothelial cells (green). Images are representative of several fields of vision taken on three separate transwells. (b) Confocal microscopy images indicate areas of actin polymerization on MDDCs treated with CCL2 (100 ng/ml) for indicated durations and labeled with phalloidin-FITC. All images were taken at 63X. Scale bar: 25 μm. Flow cytometry histograms show staining intensity of (c) MDDCs and (d) monocytes at different time points indicating more (right shift) or less (left shift) addition of actin subunits in reference to the control (red line). (e) Identification of SHP1/2 and Syk phosphorylation in MDDCs upon CCL2 treatment. (f) Phalloidin-FITC histograms on WIP- and WIP+ MDDCs upon SHP1/2 inhibition (30 μM) for 3 h or Syk inhibitor (piceatannol, 30 μM) for 1 h. Histograms are representative of results from two individual donors. (See also Figure S5).
Figure 5. Impact of anti-CLEC12A antibody treatment on EAE severity and restoration in body weight. (a) Splenocytes and cLN cells from control and EAE mice were phenotyped for immune cell markers and further stained individually for CLEC12A expression. Plots represent CLEC12A GMFI levels of all animals in each group analyzed (n = 5) with the mean GMFI expression represented for each marker. (b) Data points indicating mean (n = 5) clinical disease score of C57BL/6 mice from control, EAE + IgG isotype and EAE + anti-CLEC12A antibody treatment on Day 7 (left panel). The body weight of control, EAE and Day 7 treated mice are shown on the right. (c) Data points indicating mean (n = 5) clinical disease score of SJL/J mice from EAE + vehicle and EAE + CLEC12A antibody treatment (Day 14 & Day 21) (left panel). The body weight of EAE and anti-CLEC12A antibody-treated mice are shown on the right. (d) Data points indicating mean (n = 5) clinical disease score (left) of C57BL/6 mice with EAE and C57BL/6 mice with/without CLEC12A and with/without EAE. The body weights of mice are shown on the right. *P < 0.01 and **P < 0.005.
Figure 6. CLEC12A antibody treatment blocks DC infiltration within CNS tissue of EAE mice. (a) Spinal cord tissue from C57BL/6 mice was subjected to immunoflorescence staining with anti-CD11c (green), anti-MOG antibodies (red) and DAPI (blue). Images show demyelination (white arrows) and visual enumeration of CD11c+ DCs (white box) in areas of MOG staining at 10X resolution from control, EAE and Day 7 anti-CLEC12A treated mice. Numbers represent counts from ten fields of vision from three to four sections per mouse. (b) CD11c+ DC infiltration in areas near blood vessel of spinal cord. (c) Spinal cord tissue from EAE and Day 7 anti-CLEC12A treated mice C57BL/6 mice were subjected to immunoflorescence staining with anti-CD11b (Red), anti-CD19 (Green) antibodies and DAPI (blue) for myeloid cell infiltration. (d) LFB and H&E staining from SJL/J brain tissue depicting areas of myelination (blue) and cellular infiltration (black), respectively. Data presented is representative of two mice per group. For all 10x and 20x images, Scale bar: 100μm and for 4x images, Scale bar: 200μm
Figure 7. Quantification and functional analysis of myeloid cells within the spleen upon CLEC12A antibody treatment of both progressive and relapse-remitting EAE mice. (a) Splenocytes from C57BL/6 mice with control IgG isotype, EAE + IgG isotype and EAE + CLEC12A antibody treatment (Day 7) were stained for indicated immune cell markers for quantification. Each point represents absolute count of each individual marker for each animal in every group analyzed (n = 5) with a bar that represents mean count for each marker. (b) CD11c+ cells expressing both MHCII and CD86 from splenocytes with and without MOG35–55 stimulation for 3 days followed by activation with cell activation cocktail A for 5h. Each point represents percentage of each individual marker for every group analyzed (n = 5) with a bar that represents mean percentage for each marker (right). Flow cytometric contour plots (left) showing one representation of MHCII+/CD86+ co-expression for all groups of
mice. (c) Splenocytes from three mice were also evaluated for MHCII+ expression on CD11c+ cells and CD80 and CD86 markers upon no treatment and anti-CLEC12A antibody treatment. Representative expression is shown. (d) Splenocytes from five mice were evaluated for CD69+ expression on CD4+ and CD8+ T-cells upon no treatment and anti-CLEC12A antibody treatment. Representative expression is shown. Flow cytometry analysis representing CD4+ cells expressing IL17A (top) and CD25+/FOXP3+ (bottom) from C57BL/6 and SJL/J mice upon (e) MOG35-55 and (f) PLP185-191 stimulation respectively for 3 days followed by activation for 5h. Each bar represents mean percentage for every marker per group (n = 5). Representative flow cytometry dot plots from one animal per group are shown on the left. (g) Flow cytometry analysis representing CD4+ cells expressing MOG35-49 IAB+/IFN-γ+ from control anti-Rat IgG2a, EAE + anti-Rat IgG2a and EAE + CLEC12A antibody-treated (Day 7) C57BL/6 mice with and without MOG35-55 stimulation for 3 days followed by activation for 5h. Each point represents percentage of each individual treatment for every group analyzed (n = 5) with a bar that represents mean percentage for each marker (bottom). *P < 0.01 and **P < 0.005.

**Discussion**

CD11c+ DCs have been shown to be sufficient to reactivate myelin-specific T cells thus initiating the autoimmune demyelinating disorder characterized by the EAE model46. Further, antigen presentation by myeloid DCs has been implicated in driving progression of relapsing EAE47. CLEC12A, highly expressed on both mouse and human DCs, contains a single ITIM in its cytoplasmic tail that can associate with the signaling phosphatases SHP-1 and SHP-2 and seemed to be important for the migratory phenotype seen in DCs. Phosphoproteomic analysis of MDDCs upon CCL2 treatment showed that both MAPK and WIP/WASP protein complexes were phosphorylated. The actin cytoskeletal organization of podosomes is based on a WASP- and Arp2/3-mediated mechanism and it is the intact WIP–WASP complex that stabilizes DC podosomes44, 45. Upon inhibition of SHP-1/2 phosphorylation, there was decreased actin polymerization on WIP+ DCs. Mice administered with the anti-CLEC12A antibody both prior as well as after disease onset showed significant attenuation of disease with decrease in demyelination and CD11c+ DC infiltration. Analysis of peripheral organs in antibody administered mice showed a restoration of spleen DC levels, decrease in CCR2 expression, and a peptide specific response steering T cell proliferation away from the autoimmune TH17 response. In both strains of mice, we targeted CLEC12A after the priming of T cells by APCs and when migration of T cells and APCs to the CNS has taken place3. CLEC12A, being a C-type lectin receptor can also play a role in uptake of self-antigen and presentation to T cells during disease initiation. In knockout mice, delayed disease induction indicates that this receptor may be important for antigen uptake as well as disease propagation. However, induction of EAE can also be initiated and propagated by other cell types within the CNS such as the microglia and we are able to see initiation of disease albeit delayed. Absence of CLEC12A in mice can give rise to other compensatory mechanisms, upregulating other C-type lectin receptors that can help in antigen uptake and binding of cells to the microvascular endothelium, allowing cells to migrate and maintain a diseased state in vivo. Therefore, targeting CLEC12A during ongoing disease is more effective in curbing inflammation due to its relevance during disease state.

Here, we found CLEC12A to be involved in binding and transmigration of DCs across the BBB. CLEC12A is expressed on cells of myeloid lineage including monocytes, macrophages and DCs46–48, validating it as a myeloid-specific target for further study. Interestingly, CLEC12A is highly N-glycosylated and the degree of glycosylation varies significantly in different leukocyte populations42, 43, which may ultimately have functional consequences for ligand binding. Not long ago, CLEC12A was shown to sense monosodium urate microcrystals (MSU) from dying cells thereby responding to noninfectious inflammation, giving this receptor importance in autoimmunity and inflammatory disease44. However, bone marrow, spleen, and kidney all possess endogenous ligands to CLEC12A, that are yet to be characterized45. Our data suggests that there is a ligand on endothelial cells of the BBB as well.

A more recent study showed that CLEC12A−/− mice develop exacerbated disease in a collagen antibody-induced arthritis (CAIA) model. Antibody administration against CLEC12A in wild type mice also resulted in a similar phenotype45. However, CAIA is highly driven by autoantibody effects unlike MOG-peptide induced EAE46. CLEC12A as a regulator of inflammatory control was first demonstrated when i.p. injections of MSU and subsequent injections with dead kidney cells induced inflammatory responses in the mice44. Here, hyper responsiveness from MSU injections is unlike EAE where high serum uric acid (UA) levels has been shown to reverse the disease progression47, 48 due to a protective role of UA in EAE and MS49, 50 owing to its peroxynitrite scavenging activity51, 52. Blocking of CLEC12A could thus prove beneficial in maintaining UA levels resulting in neuroprotection in addition to the vivo-produced benefits due to the impaired migration ability of DCs.

Phosphorylation of CLEC12A ITIM receptor allows recruitment of SH2 domain-containing protein tyrosine phosphatases (PTP), such as -1, SHP-2, and SHIP that dephosphorylate various protein tyrosine kinases, adaptor molecules, or enzymes to balance or suppress the activating signaling. However, it is now acknowledged that ITIM mediated SHP-1 and SHP-2 signaling, including signaling through CLEC12A, can have activating properties including phosphorylation of p38MAPK, ERK, increased cytokine expression, upregulation of CCR7, TLR2 and TLR4, thus indicating increased DC maturation, migration and antigen processing53, 54, 55, 56. A recent study has shown another such phosphatase, PTPN12 is important for the migration of DCs55. However, the exact events following antibody binding to CLEC12A are yet to be elucidated. Binding of antibody may lead to receptor neutralization thereby making it unavailable to bind to ligands at the BBB and inhibit migration and activation pathways. It may also lead to receptor internalization and subsequent activation of the CLEC12A receptor resulting in...
phosphorylation of SHP thereby triggering a slew of anti-inflammatory molecules and an inhibition of function (Supplementary Figure 8).

Our study brings forward a clinically viable target to inhibit myeloid cell migration. It is now acknowledged that CNS-infiltrating DCs are crucial for restimulation of co-infiltrating T-cells.23, 25, 36, 39 So far, specific depletion of β1 integrins on DCs has shown reduced adhesion of DCs to the BBB40, but non-selectively. Hence, we believe efforts should be now spent in devising therapies based on myeloid-specific cell contacts, namely the CLRs investigated here, as these molecules have been historically studied for their roles in adhesion to cells and pathogens22 and can serve as promising candidates to curb the propagation of inflammation within the CNS.

Methods

Isolation of dendritic cells from blood. Peripheral blood mononuclear cells (PBMCs) were isolated from heparinized blood (Biology Speciality Corporation) by Ficoll-Paque Plus (Amersham Biosciences) density gradient centrifugation. Monocytes obtained by the adherence method from PBMCs were cultured in 1% normal human plasma (Sigma-Aldrich) in the presence of rhGM-CSF (100 IU/ml; PeproTech) and rhIL-4 (300 IU/ml; PeproTech) for 5 days. Cells were provided with fresh cytokines every other day. pDCs and mDCs isolation from PBMCs was carried out by magnetic separation with a MACS Separator (Miltenyi Biotec) according to manufacturer’s protocol.

Flow cytometric phenotyping of CLRs on MDDCs and isolated mDCs. The purity of MDDCs and mDCs were verified by flow cytometry, and shown to be ~90% pure for CD11c and CD1c respectively. The DCs were stained for C-type lectins using anti-CD205, -CLEC4A, -CLEC9A, -CLEC10A, -CLEC12A (Biolegend) and -CD303 (Miltenyi Biotec) antibodies conjugated to PE. FACS data was acquired on BD FACS Calibur (BD Biosciences, San Jose, CA, USA) and analyzed with FlowJo software (Tree Star).

Dendritic cell-brain endothelial cell adhesion assay. Human endothelial cells (hCMEC/D3) obtained from Dr Pierre-Olivier Courard (Institut Cochin, Paris, France) were seeded into collagen-coated (50 μg/ml; Trevigen) wells of a 96-well microplate (BD Biosciences) in complete EBM-2 media (Lonza) until 100% confluency was reached. TNF-α (R&D Systems) (100 U/μl) was also later added to some endothelial cell layers for 8 h to simulate the inflamed BBB through upregulation of receptor molecules.

MDDCs and mDCs were treated with varying doses (15, 25, 50 μg/ml) of specific anti-lectin antibodies namely, anti-CD205, -CLEC4A, -CLEC9A (R&D systems) and CD206, -CLEC12A (Biolegend), CD209 (BD Biosciences) and incubated for 1 h for blocking these receptors. Untreated cells were set aside to be used as positive controls. DCs were then labeled with calcein AM fluorescent dye (5 μl/ml; Invitrogen) and added to each well of endothelial cells (non activated and activated) and incubated for 1 h to allow for binding to take place. A separate well was filled with 300,000 DCs, acting as a positive control for the fluorescent value of the total cells originally added. After 4 washes with RPMI, wells were filled with PBS and fluorescence was read by a multi-well plate reader (BioTek) at an excitation of 494 nm and an emission of 517 nm. Values were obtained and plotted as fluorescence unit (F.U.) from triplicate data, which was then statistically analyzed using a student’s t test to compare the difference in binding levels between the control and the experimental groups.

Transendothelial migration assay. 1 million primary MDDCs, mDCs and PBMCs cells were transferred to the upper chamber of polyethylene terephthalate transwells in the monolayer BBB model and allowed to transmigrate for 24 h across TNF-α (100 U/ml) activated endothelial cell layers grown on 8-micron membrane inserts. Cells were first treated with varying doses (15 and 30 μg/ml) of lectin blocking antibody as indicated previously and incubated for 1 h. Where indicated, CCL2 (R&D Systems) was added to the lower chamber (100 ng/ml) at the same time as immune cells were added to the upper chamber. At 24 h, transmigrated cells from the bottom chamber were removed and counted by trypan blue exclusion. Similarly, murine splenic DCs were isolated using the EasySep Mouse CD11c Positive Selection Kit (STEMCELL Technologies) and 1 million Calcein AM labeled DCs were added to the upper chamber of the transwells in the presence of blocking antibodies against CLEC12A, CLEC12A isotype control and CLEC4A (30 μg/ml; R&D Systems) and allowed to transmigrate for 2 h across murine endothelial cells, bEnd.3 (ATCC), that were grown and activated on 8-micron membrane inserts. At 2h, transmigrated cells were imaged using an inverted fluorescent microscope and the images were analyzed using ImageJ.

CCL2-driven SHP1/2 and Syk phosphorylation and actin polymerization. MDDCs were treated with CCL2 for 30 min, collected, fixed, permeabilized and stained with anti-SHP-2 (pY542) and anti-Syk (pY348) antibodies (BD Biosciences) to detect phosphorylation. For actin polymerization detection, CCL2 treated (+CCL2) and CCL2 untreated (-CCL2) mDCs were revealed using anti-WIP (pS488) antibody (BD Biosciences) and phalloidin to check phalloidin levels of podsomal DCs. Phallolidin levels were specifically analyzed on WIP + and WIP − gated CD11c + MDDCs.

Sample preparation and phosphopeptide enrichment. Cell lysates were prepared from untreated and CCL2 treated (30 μg/ml) MDDCs. The cells were lysed in cell lysis buffer (Thermo Scientific) in the presence of protease inhibitor (Complete; Roche) and phosphatase inhibitor (PhosphoSTOP; Roche). After brief sonication and centrifugation, the soluble protein supernatants were separated from the insoluble debris. Protein concentrations were measured by Bradford protein assay (Bio-Rad). 400 μg of protein from control and treated was digested
using the modified FASP procedure (filter aided sample preparation). Lysates were placed on a 5Kda filter device and wash with 100mM NH₄HCO₃ to remove detergent. Samples were reduced with 100mM DTT and alkylated with 50mM iodoacetamide. Denatured proteins were digested with sequencing grade trypsin (Promega) in solution using a protein to trypsin ratio of 50:1 at 37 °C chamber overnight. For phosphopeptide enrichment, the samples were desalted and enriched using TiO₂ enrichment kit according to manufacturer's instruction (Thermo Scientific). Each of the enriched peptide samples was desalted and stored at −20 °C before analysis.

Phosphopeptide analysis by LC-MS/MS. Mass spectrometry experiments were carried out using LTQ-Orbitrap Velos instruments (Thermo Electron) interfaced with nano ultimate high-performance liquid chromatography (HPLC, Dionex). As a part of the online sample clean-up step, the peptides were first concentrated using a 300 μm ID × 5 mm C18 RP trap column (Dionex) and then separated using a 75 μm ID × 15 cm C18 RP analytical column (Dionex), equilibrated in 4% ACN/0.1% FA at 250nL/minute flow rate. Mobile phase A was 2% ACN and 0.1% FA in water, whereas mobile phase B was 0.1% FA and 90% ACN in water. Peptides were separated with a gradient of 4–50% B in 60 minutes and 50–80% in 90 minutes and eluted directly into the mass spectrometer. The mass range in MS mode was 350 Da–1500 Da and in MS/MS mode it was set as 100 Da–1500 Da. The peptides were analyzed using a data-dependent method. Examples of the mass spectrometry data from phosphoproteomics of two such identified peptides (Supplementary Figure 5, MAPK6-top panel and SRC8 cortactin-bottom panel) are shown. A total of 92 phosphopeptides were present in treatment sample as compared to 101 phosphopeptides present in control sample (Supplementary Tables 1 and 2). Among those phosphopeptides, 99 phosphopeptides with unique phosphorylation site from were identified in the treatment sample (Supplementary Table 3).

Database search and pathway analysis. The acquired spectra data were searched against Swissprot protein database using Proteome Discoverer 1.3 (Thermo Scientific) to interpret data and derive peptide sequences with the following parameters: partial-trypsin specificity, peptide mass tolerance of ±20ppm, fragment ion mass tolerance of ±0.8 Da, maximum missed cleavages of 2, variable modifications of methionine oxidation, phosphorylation of serine, threonine, tyrosine and cysteine carbamidomethylation. The search results were filtered with cross-correlation (Xcorr) via charge states (≥1:1.5, ≥2:2.0, ≥3:2.25, ≥4:3.0), delta correlation (∆Cn > 0.1). A stringent 1% false discovery rate threshold was used to filter candidate peptide, protein and phosphosite identifications. Individual phosphopeptide fraction datasets (common protein with common phosphorylation site in both groups or unique protein/common protein with unique phosphorylation site in treatment group) were collated and analyzed using Pathway studio software (Elsevier) to uncover biological processes and molecular functions that are over or under expressed amongst the cognate proteins corresponding to the CCL2 treatment (P < 0.01).

Mice. Female C57BL/6 mice and SJL/J (6–8 weeks old) were purchased from the National Cancer Institute (Rockville, MD, USA). CLEC12A−/− mice were generated as described previously44 and these mice and the corresponding wild-type controls were kindly provided by Drs. Konstantin Neumann and Jürgen Ruland from Institut für Klinische Chemie und Pathobiochemie, Technische Universität München, Munich, Germany.

Ethics statement. Animals were housed at the AAALAC-accredited University of South Carolina, School of Medicine (Columbia, SC, USA). All animal procedures were performed according to NIH guidelines under protocols approved by the Institutional Animal Care and Use Committee of the University of South Carolina. All studies involving animals are in accordance with the ARRIVE guidelines for reporting experiments involving animals.

Evaluation of anti-CLEC12A antibody in EAE immunized mice. Progressive EAE was induced in female C57BL/6 mice (6–8 weeks old) and the CLEC12A−/− mice as described previously. Briefly, 100 μL of 150 μg myelin oligodendrocyte glycoprotein (MOG35–55) (PolyPeptide Laboratories) peptide emulsified in complete Freund's adjuvant (Difco) containing 4 mg/ml Mycobacterium tuberculosis (strain H37Ra; Difco) was injected subcutaneously. Following immunization, 200 ng of pertussis toxin (List Labs) was injected i.p. into mice on Day 0, followed by a 400 ng pertussis toxin i.p. injection on Day 2. Animals were randomized into groups and anti-CLEC12A antibody (100 μg; R&D systems) was administered i.p. on Day 7 after induction of EAE in one group of mice (n = 5). The anti-CLEC12A antibody used in this study was raised against Thr67-Arg267 peptide of mouse-myeloma cell line derived recombinant CLEC12A and has been previously used for the successful detection of murine CLEC12A44. IgG isotype (100 μg; R&D Systems) antibody was administered in naive mice (n = 5) and EAE induced mice (n = 5) as a control. On Day 28, mice were sacrificed and spleen, cLNs, brain and spinal cord were harvested. For the KO studies, wild type and CLEC12A−/− mice were immunized as described above, observed and scored for EAE symptoms and sacrificed on day 26. Paraffin-embedded sections (10 μm) were prepared from the spleen of the CLEC12A−/− and wild-type mice for testing anti-CLEC12A antibody specificity. Immunofluorescence detection of CLEC12A, CLEC4A (320511; R&D Systems), and CD11c was carried out using Pathway studio software (Elsevier) to uncover biological processes and molecular functions that are over or under expressed amongst the cognate proteins corresponding to the CCL2 treatment (P < 0.01).
Histological analysis of demyelination and myeloid cell infiltration. CNS tissue from naive + IgG isotype antibody, EAE + IgG isotype antibody or EAE + anti-CLEC12A antibody Day 7 were collected and fixed with 10% formalin and paraffin blocks were prepared. Microtome sections (10 μm) were generated and stained with 1:50 anti-CD11c (clone AP-MAB0806; Novus Biologicals), 1:100 anti-CD11b (polyclonal; Novus Biologicals), 1:50 anti-CD19 (6D5; Biologie) and 1:50 anti-MOG antibody (polyclonal; Thermo Scientific). Brain tissue was further subjected to Luxol Fast Blue/Cresyl Violet staining (Novaultra), followed by hematoxylin & eosin (Polyscientific).

Quantification of immune cells and stimulation with antigenic peptides. Spleen and cLN were homogenized separately into a single-cell suspension and spleen tissue was subjected to red blood cell lysis. Cells were stained with anti-CD11c, anti-CD11b, anti-CD68, anti-CD4, anti-CD8a (Biolegend) and further stained individually for CLEC12A expression. Immune cell markers and further stained for CCR2 receptor on each cell-type. Splenocytes were stained with anti-CD11c, anti-CD11b, anti-CD68, anti-CD4, anti-CD8a (Biolegend) and anti-CCR2 (R&D antibodies) staining using BD Cytofix/CytoPerm Fixation/Permeabilization Solution Kit. Cells were then acquired and analyzed for intracellular cytokines using the flow cytometer.

Statistics. For comparisons between groups (control, EAE + IgG2a isotype antibody and EAE + anti-CLEC12A antibody), a two-tailed, unpaired nonparametric t test was used (Mann–Whitney). To determine the significance within a group, a two-tailed, paired nonparametric t test was used (Wilcoxon matched pairs test). The comparison was determined to be significant (*) if the P value was less than or equal to (≤) 0.05, very significant (**) if ≤0.01, and extremely significant (***) if ≤0.001. Statistical values were obtained using Prism version 4 C software (Graphpad Software Inc.).

References
1. Loma, I. & Heyman, R. Multiple sclerosis: pathogenesis and treatment. *Curr Neuropharmacol* 9, 409–416, doi:10.2174/157015911796557911 (2011).
2. Sagr, D. et al. Dendritic cell CNS recruitment correlates with disease severity in EAE via CCL2 chemotaxis at the blood-brain barrier through paracellular transmigration and ERK activation. *J Neuroinflammation* 9, 245, doi:10.1186/1742-2094-9-245 (2012).
3. Sosa, R. A., Murphey, C., Ji, N., Cardona, A. E. & Forsthuber, T. G. The kinetics of myelin antigen uptake by myeloid cells in the central nervous system during experimental autoimmune encephalomyelitis. *J Immunol* 191, 5848–5857, doi:10.4049/jimmunol.1300771 (2013).
4. Vednock, T. A. et al. Prevention of experimental autoimmune encephalomyelitis by antibodies against alpha 4 beta 1 integrin. *Nature* 356, 63–66, doi:10.1038/356063630 (1992).
5. Boster, A. L. et al. Lessons learned from fatal progressive multifocal leukoencephalopathy in a patient with multiple sclerosis treated with natalizumab. *JAMA Neurol* 70, 398–402, doi:10.1001/jamaneurol.2013.1960 (2013).
6. Tortorella, C., Durezzo, V., D’Onghia, M. & Troiano, M. Brainstem PML lesion mimicking MS plaque in a natalizumab-treated MS patient. *Neurology* 81, 1470–1471, doi:10.1212/WNL.0b013e31825079c (2013).
7. Brocke, S., Piercy, C., Steinman, L., Weissman, I. L. & Veromaa, T. Antibodies to CD44 and integrin alpha4beta1, but not L-selectin, prevent central nervous system inflammation and experimental encephalomyelitis by blocking secondary leukocyte recruitment. *Proc Natl Acad Sci USA* 96, 6896–6901 (1999).
8. de Andres, C. et al. Long-term decrease in VLA-4 expression and functional impairment of dendritic cells during natalizumab therapy in patients with multiple sclerosis. *PLoS One* 7, e34103, doi:10.1371/journal.pone.0034103 (2012).
9. Rahman, S. et al. Unique Cytokine/Chemokine Signatures for HIV-1 and HCV Mono-infection versus Co-infection as Determined by the Lumines(R) Analyses. *J Clin Cell Immunol* 2, doi:10.4172/2155-9899.1000104 (2011).
10. Mindur, J. E., Ito, N., Dhib-Jalbut, S. & Ito, K. Early treatment with anti-VLA-4 mAb can prevent the infiltration and/or development of pathogenic CD11b+CD4+ T cells in the CNS during progressive EAE. *PLoS One* 9, e99068, doi:10.1371/journal.pone.0099068 (2014).
11. Dijkstra, C. D., De Groot, C. J. & Huitinga, I. The role of macrophages in demyelination. *J Neuroimmunol* 163, 113–121 (1989).
12. Moreno, M. et al. Conditional ablation of astroglial CCL2 suppresses CNS accumulation of M1 macrophages and preserves axons in mice with MOG peptide EAE. *J Neurosci* 34, 1470–1471, doi:10.1523/JNEUROSCI.0220-14.2014 (2014).
13. Vainchtein, I. D. et al. In acute experimental autoimmune encephalomyelitis, infiltrating macrophages are immune activated, whereas microglia remain immune suppressed. *Glia* 62, 1724–1735, doi:10.1002/glia.22711 (2014).
14. Clarkson, B. D. et al. Mapping the accumulation of co-infiltrating CNS dendritic cells and encephalitogenic T cells during EAE. *J Neuroimmunol*, doi:10.1016/j.jneuroim.2014.09.016 (2014).
15. Dittl, B. N., Visentin, I., Merchant, R. M. & Janeway, C. A. Jr. Presentation of the self antigen myelin basic protein by dendritic cells leads to experimental autoimmune encephalomyelitis. *J Immunol* 163, 32–39 (1999).
16. Gautam, A. M. & Glynn, P. Lewis rat lymphoid dendritic cells can efficiently present homologous myelin basic protein to encephalitogenic lymphocytes. *J Neuroimmunol* 22, 113–121 (1989).
17. Hatterer, E., Touret, M., Belin, M. F., Honnorat, J. & Nataf, S. Cerebrospinal fluid dendritic cells infiltrate the brain parenchyma and target the cervical lymph node under neuroinflammatory conditions. *PLoS One* 3, e3321, doi:10.1371/journal.pone.0003321 (2008).
18. Woalarczyk, A., Lobner, M., Cedile, O. & Owens, T. Comparison of microglia and infiltrating CD11c(+) cells as antigen presenting cells for T cell proliferation and cytokine response. *J Neuroinflammation* 11, 57, doi:10.1186/1742-2094-11-57 (2014).
19. Wu, G. F. et al. Limited sufficiency of antigen presentation by dendritic cells in models of central nervous system autoimmunity. *J Autoimmun* 36, 56–64, doi:10.1016/j.jaut.2010.01.006 (2011).
57. Chen, C. H.
56. Hertzenberg, D.
55. Hooper, D. C.
54. Kutzing, M. K. & Firestein, B. L. Altered uric acid levels and disease states.
53. Sotgiu, S.
52. Barrow, A. D. & Trowsdale, J. 
51. You say ITAM and I say ITIM, let’s call the whole thing off: the ambiguity of immunoreceptor
50. Moccia, M.
49. Scott, G. S.
48. Redelinghuys, P.
47. Neumann, K.
46. Pyz, E.
45. Marshall, A. S.
44. Bakker, A. B.
43. Cambi, A. & Figdor, C. G. How C-type lectins detect pathogens.
42. Weksler, B. B.
41. Arjmandi, A., Liu, K. & Dorovini-Zis, K. Dendritic cell adhesion to cerebral endothelium: role of endothelial cell adhesion molecules
40. Arjmandi, A., Liu, K. & Dorovini-Zis, K. Dendritic cell adhesion to cerebral endothelium: role of endothelial cell adhesion molecules and their ligands. 
39. Martinez-Quiles, N., Koopman, M. & Figdor, C. G. Dual function of C-type lectin-like receptors in the immune system.
38. Cambi, A. & Figdor, C. G. Dual function of C-type lectin-like receptors in the immune system.
37. Engelhardt, B. Immune cell entry into the central nervous system: involvement of adhesion molecules and chemokines.
36. Marder, B. D. Immune cell entry into the central nervous system: involvement of adhesion molecules and chemokines.
35. Weiss, R. S. Immune cell entry into the central nervous system: involvement of adhesion molecules and chemokines.
34. Marder, B. D. Immune cell entry into the central nervous system: involvement of adhesion molecules and chemokines.
33. Weiss, R. S. Immune cell entry into the central nervous system: involvement of adhesion molecules and chemokines.
32. Weiss, R. S. Immune cell entry into the central nervous system: involvement of adhesion molecules and chemokines.
31. Weiss, R. S. Immune cell entry into the central nervous system: involvement of adhesion molecules and chemokines.
30. Weiss, R. S. Immune cell entry into the central nervous system: involvement of adhesion molecules and chemokines.
29. Weiss, R. S. Immune cell entry into the central nervous system: involvement of adhesion molecules and chemokines.
28. Weiss, R. S. Immune cell entry into the central nervous system: involvement of adhesion molecules and chemokines.
27. Weiss, R. S. Immune cell entry into the central nervous system: involvement of adhesion molecules and chemokines.
26. Weiss, R. S. Immune cell entry into the central nervous system: involvement of adhesion molecules and chemokines.
25. Weiss, R. S. Immune cell entry into the central nervous system: involvement of adhesion molecules and chemokines.
24. Weiss, R. S. Immune cell entry into the central nervous system: involvement of adhesion molecules and chemokines.
23. Weiss, R. S. Immune cell entry into the central nervous system: involvement of adhesion molecules and chemokines.
22. Weiss, R. S. Immune cell entry into the central nervous system: involvement of adhesion molecules and chemokines.
21. Weiss, R. S. Immune cell entry into the central nervous system: involvement of adhesion molecules and chemokines.
20. Weiss, R. S. Immune cell entry into the central nervous system: involvement of adhesion molecules and chemokines.
19. Weiss, R. S. Immune cell entry into the central nervous system: involvement of adhesion molecules and chemokines.
18. Weiss, R. S. Immune cell entry into the central nervous system: involvement of adhesion molecules and chemokines.
17. Weiss, R. S. Immune cell entry into the central nervous system: involvement of adhesion molecules and chemokines.
16. Weiss, R. S. Immune cell entry into the central nervous system: involvement of adhesion molecules and chemokines.
15. Weiss, R. S. Immune cell entry into the central nervous system: involvement of adhesion molecules and chemokines.
14. Weiss, R. S. Immune cell entry into the central nervous system: involvement of adhesion molecules and chemokines.
13. Weiss, R. S. Immune cell entry into the central nervous system: involvement of adhesion molecules and chemokines.
12. Weiss, R. S. Immune cell entry into the central nervous system: involvement of adhesion molecules and chemokines.
11. Weiss, R. S. Immune cell entry into the central nervous system: involvement of adhesion molecules and chemokines.
10. Weiss, R. S. Immune cell entry into the central nervous system: involvement of adhesion molecules and chemokines.
9. Weiss, R. S. Immune cell entry into the central nervous system: involvement of adhesion molecules and chemokines.
8. Weiss, R. S. Immune cell entry into the central nervous system: involvement of adhesion molecules and chemokines.
7. Weiss, R. S. Immune cell entry into the central nervous system: involvement of adhesion molecules and chemokines.
6. Weiss, R. S. Immune cell entry into the central nervous system: involvement of adhesion molecules and chemokines.
5. Weiss, R. S. Immune cell entry into the central nervous system: involvement of adhesion molecules and chemokines.
4. Weiss, R. S. Immune cell entry into the central nervous system: involvement of adhesion molecules and chemokines.
3. Weiss, R. S. Immune cell entry into the central nervous system: involvement of adhesion molecules and chemokines.
2. Weiss, R. S. Immune cell entry into the central nervous system: involvement of adhesion molecules and chemokines.
1. Weiss, R. S. Immune cell entry into the central nervous system: involvement of adhesion molecules and chemokines.
58. Rhee, I., Zhong, M. C., Reizis, B., Cheong, C. & Veillette, A. Control of dendritic cell migration, T cell-dependent immunity, and autoimmunity by protein tyrosine phosphatase PTPN12 expressed in dendritic cells. *Mol Cell Biol* **34**, 888–899, doi:10.1128/MCB.01369-13 (2014).

59. Clarkson, B. D. *et al.* Mapping the accumulation of co-infiltrating CNS dendritic cells and encephalitogenic T cells during EAE. *J Neuroimmunol* **277**, 39–49, doi:10.1016/j.jneuroim.2014.09.016 (2014).

60. Zhou, J., Nagarkatti, P., Zhong, Y. & Nagarkatti, M. Immune modulation by chondroitin sulfate and its degraded disaccharide product in the development of an experimental model of multiple sclerosis. *J Neuroimmunol* **223**, 55–64, doi:10.1016/j.jneuroim.2010.04.002 (2010).

61. Singh, N. P., Hegde, V. L., Hofseth, L. J., Nagarkatti, M. & Nagarkatti, P. Resveratrol (trans-3,5,4′-trihydroxystilbene) ameliorates experimental allergic encephalomyelitis, primarily via induction of apoptosis in T cells involving activation of aryl hydrocarbon receptor and estrogen receptor. *Mol Pharmacol* **72**, 1508–1521, doi:10.1124/mol.107.038984 (2007).

62. Guan, H., Nagarkatti, P. S. & Nagarkatti, M. CD44 Reciprocally regulates the differentiation of encephalitogenic Th1/Th17 and Th2/ regulatory T cells through epigenetic modulation involving DNA methylation of cytokine gene promoters, thereby controlling the development of experimental autoimmune encephalomyelitis. *J Immunol* **186**, 6955–6964, doi:10.4049/jimmunol.1004043 (2011).

Acknowledgements

Authors wish to acknowledge US Public Health Service/National Institutes of Health grants: R56AI077414 to PJ, 1R01NS086570 to SR and NIDAT32DA007237 to AA and the Shriners Hospitals for Children grant: 85110-PHI-14 to SR. Authors would like to thank the contribution of Dr. Pierre-Olivier Couraud, Dr. Ignacio A Romero, and Dr. Babette Weksler for allowing use of the human brain endothelial cell line, hCMEC/D3. Authors also acknowledge Dr. Elizabeth Blankenhorn’s efforts in proof reading the manuscript.

Author Contributions

D.S. designed and performed majority of the experiments, framed data flow, and compiled the manuscript. M.N. and P.N. allowed EAE experimentation in their laboratory. N.S. helped in EAE induction and the antibody treatments followed by tissue collection. R.G. performed FACS analysis for confirmation of mDC purity, IHC to validate anti-CLEC12A antibody specificity using K.O. sections, D.C. migration experiment in the murine system and contributed towards editing the final manuscript. A.A. performed D.C. migration experiments in the murine cell system under the guidance of S.R. X.H. assisted in phosphoproteomic experiments and respective data analysis. R.P. helped plan the phosphoproteomic experiments alongside X.H. and D.S. K.N. and J.R. generously provided the CLEC12A−/− mice. P.J. helped conceptualize and design the study, provided expert opinion throughout the study, assisted in data interpretation, finalized and gave final approval of the version to be published. Z.K.K. thoroughly read and enriched the manuscript with important intellectual content.

Additional Information

Supplementary information accompanies this paper at doi:10.1038/s41598-017-03027-x

Competing Interests: The authors declare that they have no competing interests.

Publisher’s note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2017